NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 2.86 against a street estimate of 10.01 — a miss of 71.4%.
with an average price target of ₹134.00.
| Document | Date |
|---|---|
| Quarterly results · Q4 FY26 VIVIMED LABS LTD - DOCUMENT SUMMARY HEADLINE NUMBERS • No financial results provided in this document • Document dated 19 July 2025 is a clarificatio | 2026-06-25 |
| Quarterly results · Q3 FY26 VIVIMED LABS LIMITED – FINANCIAL RESULTS SUMMARY Q3 FY2026 (Quarter & 9 Months Ended 31 December 2025) --- HEADLINE NUMBERS STANDALONE RESULTS • Q | 2026-03-13 |
| Quarterly results · Q2 FY26 VIVIMED LABS LIMITED – DOCUMENT SUMMARY As of November 13, 2025 --- HEADLINE NUMBERS • H1 FY25 Revenue (Standalone): Rs 366.02 million (down from R | 2025-11-13 |
| Annual report FY2025 VIVIMED LABS LIMITED - ANNUAL REPORT FY 2024-25 SUMMARY HEADLINE NUMBERS • Revenue from operations: ₹1,162.69 million (FY 2024: ₹1,490.71 million) — | 2025-09-06 |
| Quarterly results · Q1 FY26 VIVIMED LABS LIMITED – FINANCIAL SUMMARY Board Meeting: August 13, 2025 --- HEADLINE NUMBERS • Q1 FY2025-26 Standalone Revenue from Operations: Rs | 2025-08-14 |
| Quarterly results | 2025-03-21 |
| Quarterly results | 2025-02-14 |
| Quarterly results | 2025-01-11 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Vivimed Labs Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.